Cargando…
TRPM2: a candidate therapeutic target for treating neurological diseases
Transient receptor potential melastatin 2 (TRPM2) is a calcium (Ca(2+))-permeable non-selective cation channel belonging to the TRP ion channel family. Oxidative stress-induced TRPM2 activation provokes aberrant intracellular Ca(2+) accumulation and cell death in a variety of cell types, including n...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943913/ https://www.ncbi.nlm.nih.gov/pubmed/29671419 http://dx.doi.org/10.1038/aps.2018.31 |
_version_ | 1783321720863588352 |
---|---|
author | Belrose, Jillian Corinne Jackson, Michael Frederick |
author_facet | Belrose, Jillian Corinne Jackson, Michael Frederick |
author_sort | Belrose, Jillian Corinne |
collection | PubMed |
description | Transient receptor potential melastatin 2 (TRPM2) is a calcium (Ca(2+))-permeable non-selective cation channel belonging to the TRP ion channel family. Oxidative stress-induced TRPM2 activation provokes aberrant intracellular Ca(2+) accumulation and cell death in a variety of cell types, including neurons. Aberrant TRPM2 function has been implicated in several neurological disorders including ischemia/stroke, Alzheimer's disease, neuropathic pain, Parkinson's disease and bipolar disorder. In addition to research identifying a role for TRPM2 in disease, progress has been made in the identification of physiological functions of TRPM2 in the brain, including recent evidence that TRPM2 is necessary for the induction of N-methyl-D-aspartate (NMDA) receptor-dependent long-term depression, an important form of synaptic plasticity at glutamate synapses. Here, we summarize recent evidence on the role of TRPM2 in the central nervous system (CNS) in health and disease and discuss the potential therapeutic implications of targeting TRPM2. Collectively, these studies suggest that TRPM2 represents a prospective novel therapeutic target for neurological disorders. |
format | Online Article Text |
id | pubmed-5943913 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-59439132018-05-24 TRPM2: a candidate therapeutic target for treating neurological diseases Belrose, Jillian Corinne Jackson, Michael Frederick Acta Pharmacol Sin Review Article Transient receptor potential melastatin 2 (TRPM2) is a calcium (Ca(2+))-permeable non-selective cation channel belonging to the TRP ion channel family. Oxidative stress-induced TRPM2 activation provokes aberrant intracellular Ca(2+) accumulation and cell death in a variety of cell types, including neurons. Aberrant TRPM2 function has been implicated in several neurological disorders including ischemia/stroke, Alzheimer's disease, neuropathic pain, Parkinson's disease and bipolar disorder. In addition to research identifying a role for TRPM2 in disease, progress has been made in the identification of physiological functions of TRPM2 in the brain, including recent evidence that TRPM2 is necessary for the induction of N-methyl-D-aspartate (NMDA) receptor-dependent long-term depression, an important form of synaptic plasticity at glutamate synapses. Here, we summarize recent evidence on the role of TRPM2 in the central nervous system (CNS) in health and disease and discuss the potential therapeutic implications of targeting TRPM2. Collectively, these studies suggest that TRPM2 represents a prospective novel therapeutic target for neurological disorders. Nature Publishing Group 2018-05 2018-04-19 /pmc/articles/PMC5943913/ /pubmed/29671419 http://dx.doi.org/10.1038/aps.2018.31 Text en Copyright © 2018 The Author(s) http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Review Article Belrose, Jillian Corinne Jackson, Michael Frederick TRPM2: a candidate therapeutic target for treating neurological diseases |
title | TRPM2: a candidate therapeutic target for treating neurological diseases |
title_full | TRPM2: a candidate therapeutic target for treating neurological diseases |
title_fullStr | TRPM2: a candidate therapeutic target for treating neurological diseases |
title_full_unstemmed | TRPM2: a candidate therapeutic target for treating neurological diseases |
title_short | TRPM2: a candidate therapeutic target for treating neurological diseases |
title_sort | trpm2: a candidate therapeutic target for treating neurological diseases |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5943913/ https://www.ncbi.nlm.nih.gov/pubmed/29671419 http://dx.doi.org/10.1038/aps.2018.31 |
work_keys_str_mv | AT belrosejilliancorinne trpm2acandidatetherapeutictargetfortreatingneurologicaldiseases AT jacksonmichaelfrederick trpm2acandidatetherapeutictargetfortreatingneurologicaldiseases |